In HER2+ breast cancer, trastuzumab, a humanized mouse monoclonal antibody against the human HER2 receptor, is an essential component of treating the HER2-positive breast cancer subtype [3] and is known to stimulate an anti-tumor immune response [4,5,6,7]. Here, ERBB2 is linked to breast carcinoma.